ImmuneOnco Biopharmaceuticals (Shanghai) (HKG:1541) plans to sell 33,150,000 shares at HK$7.05 apiece to investors under a placement deal, according to a Thursday filing with the Hong Kong Exchange.
The shares represent 8.14% of the pharmaceutical company's shareholding as enlarged by the placement.
Net proceeds of HK$229.7 million, will be used to fund studies for its non-small cell lung cancer, triple-negative breast cancer, and tumor treatments, and for working capital.
Shares slid 6% during Thursday's trading.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。